NBIO
Nascent Biotech, Inc.
Price Chart
Latest Quote
$0.00
+0.00 (+0.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 15,000 |
Stock Information
| Shares Outstanding | 172.22M |
| Total Debt | $59K |
| Cash Equivalents | $47K |
| Net Income | $-1.92M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $34K |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $46K |
| Income | $-1.92M |
| Book/sh | $-0.00 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 0.06 |
| Current Ratio | 0.31 |
Returns & Margins
| ROA | -854.34% |
Ownership
| Insider Ownership | 21.51% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.07 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.00 |
| RSI | nan |
| Shares Float | 135.39M |
| Volatility | 1.93 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| 6 Months | +0.00% |
| YTD | -66.67% |
| Year | -91.30% |
| 3 Years | -99.86% |
| 5 Years | -99.74% |
| 10 Years | -99.90% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-11-02 | $0.00 | 0 |
| 2026-10-30 | $0.00 | 10,000 |
| 2026-10-29 | $0.00 | 0 |
| 2026-10-28 | $0.00 | 0 |
| 2026-10-27 | $0.00 | 0 |
| 2026-10-26 | $0.00 | 0 |
| 2026-10-23 | $0.00 | 0 |
| 2026-10-22 | $0.00 | 0 |
| 2026-10-21 | $0.00 | 0 |
| 2026-10-20 | $0.00 | 0 |
| 2026-10-19 | $0.00 | 0 |
| 2026-10-16 | $0.00 | 0 |
| 2026-10-15 | $0.00 | 0 |
| 2026-10-14 | $0.00 | 38,073 |
| 2026-10-13 | $0.00 | 0 |
| 2026-10-12 | $0.00 | 12,000 |
| 2026-10-09 | $0.00 | 800 |
| 2026-10-08 | $0.00 | 0 |
| 2026-10-07 | $0.00 | 0 |
| 2026-10-06 | $0.00 | 0 |
| 2026-10-05 | $0.00 | 15,000 |
About Nascent Biotech, Inc.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.
đ° Latest News
No news articles available at the moment. Check back later for updates on NBIO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $1,000,000 | $750,000 |
| Operating Revenue | $0 | $0 | $1,000,000 | $750,000 |
| Expenses | ||||
| Interest Expense | $385,236 | $1,723,148 | $335,983 | $336,632 |
| Total Expenses | $2,229,879 | $2,155,757 | $1,457,052 | $2,150,368 |
| Other Income Expense | $522,168 | $1,082,786 | $473,823 | $797,644 |
| Net Non Operating Interest Income Expense | $-379,971 | $-1,727,998 | $-487,121 | $-356,038 |
| Interest Expense Non Operating | $385,236 | $1,723,148 | $335,983 | $336,632 |
| Operating Expense | $2,229,879 | $2,155,757 | $1,457,052 | $2,150,368 |
| Other Operating Expenses | $411,973 | $383,688 | $332,289 | - |
| General And Administrative Expense | $1,706,931 | $1,501,540 | $927,357 | $1,828,430 |
| Total Other Finance Cost | - | $5,124 | $151,150 | $19,411 |
| Other Non Operating Income Expenses | - | - | - | $-369 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Net Interest Income | $-379,971 | $-1,727,998 | $-487,121 | $-356,038 |
| Interest Income | $5,265 | $274 | $12 | $5 |
| Normalized Income | $-2,609,850 | $-3,883,755 | $-944,213 | $-1,756,780 |
| Net Income From Continuing And Discontinued Operation | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Total Operating Income As Reported | $-2,229,879 | $-2,155,757 | $-457,052 | $-1,400,368 |
| Net Income Common Stockholders | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Net Income | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Net Income Including Noncontrolling Interests | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Net Income Continuous Operations | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Pretax Income | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Special Income Charges | $50,000 | $28,000 | $5,000 | $151,308 |
| Interest Income Non Operating | $5,265 | $274 | $12 | $5 |
| Operating Income | $-2,229,879 | $-2,155,757 | $-457,052 | $-1,400,368 |
| Per Share | ||||
| Diluted EPS | $-0.01 | $-0.02 | $-0.00 | $-0.01 |
| Basic EPS | $-0.01 | $-0.02 | $-0.00 | $-0.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,224,614 | $-2,160,607 | $-608,230 | $-1,420,148 |
| Total Unusual Items | $522,168 | $1,082,786 | $473,823 | $798,013 |
| Total Unusual Items Excluding Goodwill | $522,168 | $1,082,786 | $473,823 | $798,013 |
| EBITDA (Bullshit earnings) | $-1,702,446 | $-1,077,821 | $-134,407 | $-622,135 |
| EBIT | $-1,702,446 | $-1,077,821 | $-134,407 | $-622,135 |
| Diluted Average Shares | $155,744,233 | $118,569,028 | $107,741,761 | $72,342,193 |
| Basic Average Shares | $155,744,233 | $118,569,028 | $107,741,761 | $72,342,193 |
| Diluted NI Availto Com Stockholders | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | $-50,000 | $-28,000 | $-5,000 | $-151,308 |
| Gain On Sale Of Security | $472,168 | $1,054,786 | $468,823 | $646,705 |
| Research And Development | $110,975 | $270,529 | $197,406 | $321,938 |
| Selling General And Administration | $1,706,931 | $1,501,540 | $927,357 | $1,828,430 |
| Other Gand A | $1,706,931 | $1,501,540 | $927,357 | $1,828,430 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Total Assets | $552,120 | $255,002 | $105,414 | $751,435 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $552,120 | $255,002 | $105,414 | $751,435 |
| Prepaid Assets | $180,000 | $82,816 | $11,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $372,120 | $172,186 | $94,414 | $1,435 |
| Cash And Cash Equivalents | $372,120 | $172,186 | $94,414 | $1,435 |
| Cash Financial | $372,120 | $172,186 | $94,414 | $1,435 |
| Receivables | - | - | $0 | $750,000 |
| Accounts Receivable | - | - | $0 | $750,000 |
| Debt | ||||
| Total Debt | $122,500 | $389,591 | - | $161,736 |
| Current Debt And Capital Lease Obligation | $122,500 | $389,591 | - | $161,736 |
| Current Debt | $122,500 | $389,591 | - | $161,736 |
| Other Current Borrowings | $122,500 | $389,591 | - | $161,736 |
| Net Debt | - | $217,405 | - | $160,301 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $808,794 | $1,551,139 | $776,890 | $1,223,940 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $808,794 | $1,551,139 | $776,890 | $1,223,940 |
| Payables And Accrued Expenses | $686,294 | $498,122 | $776,890 | $760,048 |
| Payables | $686,294 | $498,122 | $776,890 | $760,048 |
| Accounts Payable | $686,294 | $498,122 | $776,890 | $636,831 |
| Other Current Liabilities | - | $663,426 | - | $302,156 |
| Current Notes Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-256,674 | $-1,296,137 | $-671,476 | $-472,559 |
| Total Equity Gross Minority Interest | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Stockholders Equity | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Retained Earnings | $-24,260,457 | $-21,622,775 | $-18,821,806 | $-18,351,416 |
| Preferred Stock Equity | - | - | - | $54 |
| Other | ||||
| Treasury Shares Number | $0 | - | - | - |
| Ordinary Shares Number | $170,594,165 | $131,764,348 | $111,313,175 | $104,834,083 |
| Share Issued | $170,594,165 | $131,764,348 | $111,313,175 | $104,834,083 |
| Tangible Book Value | $-256,674 | $-1,296,137 | $-671,476 | $-472,559 |
| Invested Capital | $-134,174 | $-906,546 | $-671,476 | $-310,823 |
| Working Capital | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Total Capitalization | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Additional Paid In Capital | $23,833,189 | $20,194,874 | $18,039,017 | $17,774,023 |
| Capital Stock | $170,594 | $131,764 | $111,313 | $104,888 |
| Common Stock | $170,594 | $131,764 | $111,313 | $104,834 |
| Preferred Stock | $0 | $0 | $0 | $54 |
| Dueto Related Parties Current | - | - | $0 | $123,217 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-1,186,066 | $-1,787,228 | $413,479 | $-986,784 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,186,066 | $-1,787,228 | $413,479 | $-986,784 |
| Cash Flow From Continuing Operating Activities | $-1,186,066 | $-1,787,228 | $413,479 | $-986,784 |
| Operating Gains Losses | $-472,168 | $-1,054,786 | $-468,823 | $-798,013 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,561,000 | $0 | $0 | $640,000 |
| Financing Cash Flow | $1,386,000 | $1,865,000 | $-320,500 | $985,000 |
| Cash Flow From Continuing Financing Activities | $1,386,000 | $1,865,000 | $-320,000 | $985,000 |
| Net Common Stock Issuance | $1,561,000 | $0 | - | - |
| Common Stock Issuance | $1,561,000 | $0 | - | - |
| Net Other Financing Charges | - | - | $-500 | - |
| Net Preferred Stock Issuance | - | - | $0 | $640,000 |
| Preferred Stock Issuance | - | - | $0 | $640,000 |
| Other | ||||
| Repayment Of Debt | $-400,000 | $-275,000 | $-520,000 | $0 |
| Issuance Of Debt | $225,000 | $1,932,000 | $200,000 | $345,000 |
| Interest Paid Supplemental Data | $0 | $11,135 | $30,027 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $372,120 | $172,186 | $94,414 | $1,435 |
| Beginning Cash Position | $172,186 | $94,414 | $1,435 | $3,218 |
| Changes In Cash | $199,934 | $77,772 | $92,979 | $-1,783 |
| Proceeds From Stock Option Exercised | $0 | $208,000 | $0 | - |
| Net Issuance Payments Of Debt | $-175,000 | $1,657,000 | $-320,000 | $345,000 |
| Net Short Term Debt Issuance | $-175,000 | $1,657,000 | $-320,000 | $295,000 |
| Short Term Debt Payments | $-400,000 | $-275,000 | $-520,000 | $0 |
| Short Term Debt Issuance | $225,000 | $1,932,000 | $200,000 | $295,000 |
| Change In Working Capital | $163,784 | $-317,335 | $911,176 | $-102,518 |
| Change In Payables And Accrued Expense | $260,968 | $-245,519 | $172,176 | $647,482 |
| Change In Prepaid Assets | $-97,184 | $-71,816 | $-11,000 | $0 |
| Change In Receivables | $0 | $0 | $750,000 | $-750,000 |
| Changes In Account Receivables | $0 | $0 | $750,000 | $-750,000 |
| Other Non Cash Items | $327,909 | $1,629,542 | $325,431 | $86,662 |
| Stock Based Compensation | $882,091 | $756,320 | $116,085 | $785,852 |
| Gain Loss On Investment Securities | $-472,168 | $-1,054,786 | $-468,823 | $-646,705 |
| Net Income From Continuing Operations | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Change In Payable | - | $-245,519 | $172,176 | $647,482 |
| Change In Account Payable | - | $-245,519 | $167,060 | $230,401 |
| Net Long Term Debt Issuance | - | - | $0 | $50,000 |
| Long Term Debt Payments | - | - | $-520,500 | $0 |
| Long Term Debt Issuance | - | - | $0 | $50,000 |
Fetched: 2026-02-02